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ABSTRACT The polymyxin colistin represents a last-resort antibiotic for multidrug-
resistant infections, but its use is limited by the frequent onset of acute drug-induced
kidney injury (DIKI). It is essential to closely monitor kidney function prior to and during
colistin treatment in order to pinpoint early signs of injury and minimize long-term renal
dysfunction. To facilitate this, a mouse model of colistin-induced nephrotoxicity was
used to uncover novel early markers of colistin-induced DIKI. Increased urinary levels of
kidney injury molecule-1 (Kim-1) as well as glycosuria were observed in colistin-treated
mice, where alterations of established clinical markers of acute kidney injury (serum cre-
atinine and albuminuria) and emerging markers such as cystatin C were inaccurate in
ﬂagging renal damage as conﬁrmed by histology. A direct interaction of colistin with re-
nal glucose reabsorption was ruled out by a cis-inhibition assay in mouse brush border
membrane vesicles (BBMV). Immunohistochemical examination and protein quantiﬁca-
tion by Western blotting showed a marked reduction in the protein amount of sodium-
glucose transporter 2 (Sglt2), the main kidney glucose transporter, in renal tissue from
colistin-treated mice in comparison to that in control animals. Consistently, BBMV iso-
lated from treated mouse kidneys also showed a reduction in ex vivo glucose uptake
compared to that in BBMV isolated from control kidneys. These ﬁndings support pathol-
ogy observations of colistin-induced proximal tubule damage at the site of the brush
border membrane, where Sglt2 is expressed, and open avenues for the study of glycos-
uria as a sensitive, speciﬁc, and accessible marker of DIKI during colistin therapy.
KEYWORDS drug-induced kidney injury, colistin, glycosuria, nephrotoxicity, proximal
tubule, Kim-1
Colistin, also known as polymyxin E, is a polypeptide antibiotic used as a last-linetreatment option against Gram-negative bacterial infections. Though its use was
phased out in the 1970s due to reports of both neuro- and nephrotoxicity and the
introduction of other antibiotics, the increase in multidrug-resistant (MDR) infections
and the lack of other treatment options has led to renewed interest in colistin in the last
decade and a half (1, 2). Because colistin was not subjected to the extensive studies
required by contemporary drug regulatory agencies during its development, the bulk
of pharmacokinetics and pharmacodynamics information on this drug and derivatives
has been accumulated only in recent years (3–6). Likewise, renewed evaluations of the
occurrence, severity, and reversibility of renal toxicity have offered a perhaps slightly
less catastrophic but still worrisome view (7–10). The most recent study among 249
patients treated with intravenous colistin reported rates of acute kidney injury (AKI),
according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline crite-
ria, as 12% and 29% after 2 and 7 days of treatment, respectively, with 7% of patients
requiring renal replacement therapy (11). A retrospective study analyzing the revers-
ibility of colistin-induced renal injury found that 75% of patients that had developed
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AKI during colistin treatment also progressed to chronic kidney disease (CKD) at a
6-month follow-up compared to 27% in the matched-control subject group (12). This
highlights the high risk of long-term renal impairment, particularly in elderly patients,
following colistin therapy.
The staple biomarker used in clinics to monitor kidney function is serum creatinine,
with estimation of the glomerular ﬁltration rate and monitoring of urine output (13).
Large efforts have been put into identifying new markers that more speciﬁcally address
the etiology of renal insult and identify or predict “subclinical” AKI before serum
creatinine elevation rather than assessing renal ﬁltration as an endpoint, with the
overall goal of avoiding the irreversibility of ongoing damage. Promising suggested
markers arising from such studies include urinary neutrophil gelatinase-associated
lipocalin (Ngal) (14) and urinary kidney injury molecule-1 (Kim-1) (15, 16). Ngal is
expressed in epithelial cells and has been successfully used in both animal (17) and
human (18, 19) studies as a marker for colistin-induced nephrotoxicity. However, it was
shown as an unsuitable marker of drug-induced kidney injury (DIKI) during colistin
treatment of urinary tract infections in a geriatric patient cohort (20) due to its
increased expression upon inﬂammation and infection (21). Urinary Kim-1 levels have
been assessed under colistin treatment in rats, with the report that it is a speciﬁc marker
of proximal tubular damage (22), with very low expression in healthy kidney tissue (23,
24). Histology is the ideal gold standard for assessing tubular injury, although not
always feasible, with Kim-1 representing an example where histological examination
and urinary output of the marker have been shown to correlate closely both in rodents
and humans (25, 26).
In this study, a mouse model of colistin-induced nephrotoxicity was established to
monitor typical and emerging biomarkers of AKI and to identify the earliest markers of
DIKI, with physiological relevance in regard to the renal injury caused by this antibiotic.
Mice treated intraperitoneally with colistin sulfate once daily for 7 days showed no
elevation in most of the biomarkers of kidney injury assessed but a marked increase in
urinary Kim-1 as well as glycosuria with comparable diagnostic ability, suggesting
urinary glucose as a novel sensitive and speciﬁc inexpensive biomarker for colistin-
induced nephrotoxicity.
RESULTS
Evaluation of clinical kidney injury markers in serum and urine. Serum samples
collected from mice 24 h after the last of seven intraperitoneal (i.p.) injections of
20 mg/kg colistin or the vehicle phosphate-buffered saline (PBS) as a control were ﬁrst
analyzed for creatinine content, the standard marker currently used to assess AKI.
Results showed no differences in creatinine between treatment groups (Fig. 1A).
Urinary albumin (proteinuria) likewise did not differ between groups (Fig. 1B). Some
colistin-treated mice showed elevated urinary cystatin C (CysC) (Fig. 1C), although the
majority did not. In contrast, a signiﬁcant, general increase in urinary Kim-1 in colistin-
treated mice was noted (Fig. 1D), indicating tubular injury. As serum creatinine did not
ﬂuctuate signiﬁcantly between mice and treatment groups, reﬂecting a comparable
glomerular ﬁltration, urinary creatinine values could be used to normalize the urinary
values measured for other biomarkers (27).
Histological examination of tubular injury and markers Ngal and Kim-1. Despite
the lack of elevation in serum creatinine and urinary albumin, with only some colistin-
treated mice showing elevations in urinary CysC upon initial analysis, histological
examination of kidney tissue from these mice showed clear signs of kidney damage in
all individuals, including tubule dilation, loss of the brush boarder membranes in the
proximal tubules, and the formation of protein casts throughout the kidney tissue (Fig.
2A, B, and G). Further histological examination for AKI markers Ngal and Kim-1 showed
increased amounts of both proteins in kidney sections from treated mice compared to
those in control mice (Fig. 2C to F, H, and I).
Urinary glucose as a marker of proximal tubule injury upon colistin treatment.
The proximal tubule is the site of renal reabsorption of virtually all organic solutes,
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which consist mainly of amino acids and glucose. Indications for proximal tubule injury
in our colistin-treated mice, as well as the elevations in tubular Kim-1 and Ngal, led us
to postulate that deﬁcits in the reabsorption of such solutes might also exist, making
them potential urinary biomarkers of colistin-induced tubular injury (28). Indeed,
animals treated with colistin exhibited signiﬁcant glycosuria (Fig. 3A). A glucose toler-
ance test (GTT) was performed after overnight starvation following the last colistin
injection to rule out pleiotropic effects on glucose tolerance by colistin treatment. The
areas under the curves (AUCs) obtained for each treatment group were not signiﬁcantly
different (P  0.3), although colistin-treated mice had a signiﬁcantly lower basal blood
glucose value after starvation than the control group, likely as a result of increased
urinary glucose excretion (Fig. 3B and C).
Colistin-induced glycosuria is caused by a reduction in the protein level of the
sodium-glucose transporter 2. Glucose renal reabsorption is a carrier-mediated pro-
cess that involves two Na-dependent transporters: sodium-glucose transporters 1
(Sglt1) and 2 (Sglt2), with Sglt2 being expressed in segment 1 of the proximal tubule
on the brush border membrane and responsible for approximately 97% of renal
glucose reabsorption (29). It was previously shown that colistin inhibits L-carnitine and
amino acid renal reabsorption by interacting with the zwitterionic/organic cation
transporter 2 (OCTN2) and the peptide transporter 2 (PEPT2) (3, 30). To assess the
inhibitory effect of colistin on glucose renal reabsorption, a cis-inhibition assay was
performed with brush border membrane vesicles (BBMV) isolated from untreated mice.
FIG 1 Clinically used markers of DIKI under colistin treatment. Serum creatinine (A), urinary albumin (B),
urinary cystatin C (C), and urinary Kim-1 (D) measured in control and colistin-treated mice. Urinary
albumin, cystatin C, and Kim-1 were normalized to urinary creatinine. n 15, two-tailed P values are
indicated, unpaired t tests.
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As glucose renal reabsorption is a Na-dependent process, uptake of glucose was
measured in the presence and absence of Na to deﬁne the Na-dependent transport
component. As expected, 90% of glucose uptake was dependent on Na (Fig. 4A). The
Na-dependent uptake of glucose was not reduced in the presence of 100 M colistin
sulfate, a concentration 20 times the estimated plasma peak concentration in our
experimental setting (31) (Fig. 4B).
The effect of colistin on the expression of Sglts was then assessed. Transporter
transcript levels measured from whole kidney pieces were comparable between the
two groups (Fig. 5A). Immunostaining showed no difference in the Sglt1 levels between
groups (Fig. 5B and C), whereas the Sglt2 staining intensity and area was markedly
reduced in colistin-treated mouse kidney sections (Fig. 5D to G). Western blots of total
membrane fractions isolated from the kidneys of individual mice conﬁrmed the reduc-
tion in Sglt2 protein amount in colistin-treated mice (Fig. 5I and J). Taken together,
colistin treatment does not seem to affect the transcription of glucose transporter Sglt1
or Sglt2 in the kidney under the treatment conditions tested here but leads to a loss of
Sglt2 protein, leading to a reduction of renal glucose uptake at the brush border
membrane.
Glucose reabsorption capacity after colistin treatment, expected to be reduced by
the observed glycosuria and reduction of Sglt2 protein level, was tested ex vivo by
performing a glucose uptake assay over 20 s in BBMV isolated from control and
FIG 2 Histological signs of DIKI induced by colistin. (A and B) Hematoxylin and eosin Y (HE) stainings of mouse kidney sections from the
control group and colistin-treated mice. (C and D) Ngal stainings. (E and F) Kim-1 stainings. Brown areas indicate positive staining. Black
arrows, tubular vacuolization and loss of brush border membrane in proximal tubules; red arrows, tubular protein casts; blue arrow, area
of staining with intact brush border membrane; 20 magniﬁcation; bar, 50 m. (G to I) Severity of AKI was assessed on a severity scale
of 0 to 5, based on (i) the presence and amount of protein casts, (ii) presence and percent area with tubular dilation, and (iii) loss and
area lacking clear brush border membrane structure. Histology severity grading of samples on a scale of 0 (no staining), 1 (mild), 2
(moderate), and 3 (intense), based on the intensity and area stained per sample. n 15 (G and H), n 9 (I).
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colistin-treated mice. A signiﬁcant reduction in the Na-dependent glucose uptake was
observed in colistin-treated mice in comparison to that in the control group (Fig. 5H).
Sensitivity and speciﬁcity of urinary biomarkers for early renal damage upon
colistin treatment. In this study, markers that were able to identify or at least partially
conﬁrm individual assessments of histologically deﬁned renal injury were the urinary
markers CysC, Kim-1, and glucose. Receiver operating characteristic (ROC) curves for
these markers, displaying the overall ability of a biomarker to detect a difference
between damaged and undamaged kidneys, deﬁned areas under the curves (AUCs) of
0.71 for CysC, 0.93 for glucose, and 1.0 for Kim-1 (Fig. 6A). Data from all treated and
untreated mice were used to generate these curves, where hematoxylin and eosin Y
(HE) severity grading was used to deﬁne damaged and undamaged kidneys. These
results indicate that urinary Kim-1 and glucose are both more sensitive and speciﬁc for
the renal injury incurred under our colistin treatment regime than CysC. Interestingly,
urinary Kim-1 and glycosuria had a tendency toward a negative correlation in colistin-
treated mice (Fig. 6B). Urine samples were also collected during the course of treatment
and analyzed for both glucose and Kim-1 content (Fig. 6C and D). Increases from initial
baseline values in colistin-treated mice were observed for both markers as early as 24
h after the ﬁrst treatment.
DISCUSSION
The clinically used staple marker for assessing AKI per KDIGO guidelines is serum
creatinine. In this study, colistin-treated mice did not exhibit increased serum creatinine
(Fig. 1), but histological grading of HE stainings showed clear signs of damage in the
kidneys of all colistin-treated animals (Fig. 2). However, other studies performed in mice
using similar colistin sulfate doses and treatment durations have indeed shown eleva-
tions in serum creatinine (32–34). Differing mouse strain, sex, age, route of administra-
tion (intravenous [i.v.] versus i.p.), dosing regimens (twice daily half doses versus once
daily full dose), and creatinine quantiﬁcation method (Jaffe’s method versus an enzy-
matic method) may all have affected the apparent severity of renal damage in such
experiments. Overall, it appears that in this study, renal injury may have been induced
to a less severe degree (subclinical) than in past studies, underlining the suitability of
our model for assessing the ﬁrst signs of AKI upon colistin administration. Stressing the
fact that recent studies have shown the possible severity and irreversibility of conse-
quences of short-term colistin treatment, it is of great importance to use such models
to identify the earliest signs of renal damage that can be used to diagnose the onset
of AKI while it is still subclinical (11, 12). The subclinical AKI pattern shown here also
grants the advantage of being able to use the individual urinary creatinine values for
FIG 3 Urinary and systemic blood glucose in mice treated with colistin. (A) Urinary glucose quantiﬁed in urine
samples collected from each mouse after the ﬁnal i.p. injection of a 7-day treatment course, normalized to urinary
creatinine. n  13, two-tailed P value is indicated, unpaired t test. (B) Blood glucose values measured in tail blood
samples from control and colistin-treated mice after overnight starvation. n 10, two-tailed P value is indicated,
unpaired t test. (C) Glucose tolerance test of control and colistin-treated mice performed by measuring glucose in
tail-tip blood before and after injection of 1 g/kg D-glucose in solution.
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normalization purposes, correcting for urine concentration and output volume differ-
ences, allowing the avoidance of the use of single-housing metabolic cages. However,
it is important to stress the concept that this normalization method would not be
suitable in any case of clinical AKI, where creatinine excretion is impaired (35–37).
In this study, glycosuria correlated with the renal injury observed upon histological
examination. Colistin treatment did not have an effect on overall glucose tolerance yet
lowered blood glucose values in starved mice, likely due to the lower glucose reab-
sorption capacity (Fig. 3). Because pharmacological inhibition of Sglt2-mediated glu-
cose reabsorption effectively reduces blood glucose levels in patients with type 2
diabetes (38), the reduction of Sglt2 protein level at the brush border membrane offers
the explanation for the glycosuria observed in these mice (Fig. 5). The comparative
marker performance analysis relative to urinary Kim-1 and CysC suggests that glycos-
uria can be used as an early indicator of subclinical AKI upon colistin administration
(Fig. 6). The Kim-1 ROC AUC of 1.0 in this study is comparable to other ﬁndings (26, 39),
whereas glycosuria shows an AUC of 0.93, showing that both markers have high
sensitivity and speciﬁcity for colistin-induced AKI. The interesting ﬁnding that urinary
Kim-1 levels did not correlate with urinary glucose in samples collected after 7 days of
colistin treatment suggests that both markers can offer separate and equally relevant
information on early renal injury. The time course of urinary Kim-1 values upon renal
FIG 4 Ex vivo cis-inhibition assay. (A) Glucose uptake over 20 s in buffer containing Na (NaCl) or in
Na-free buffer (KCl). (B) Na-dependent uptake of glucose in the presence of colistin sulfate at the
indicated concentration. Values were normalized to total protein content, n 3, two-tailed P values are
indicated, unpaired t tests.
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injury underlie (i) increased expression initiated by renal insult, (ii) cleavage by a
metalloproteinase in stressed cells under the control of the mitogen-activated protein
(MAP) kinase signaling pathway, and ﬁnally, (iii) excretion of the protein in the urine (16,
40, 41). We conclude through this study that glycosuria under colistin treatment is
caused by decreased absorptive capacity of the proximal tubule through the decrease
of Sglt2 at the brush border membrane. This denotes glycosuria as a possible measure
of brush border membrane integrity and function, in regard to glucose reabsorption,
whereas urinary Kim-1 may additionally be inﬂuenced by other gene regulatory,
posttranslational, or cell-stress mediated mechanisms (42). Additional studies would be
FIG 5 Glucose transporter mRNA, protein, and transport capacity under colistin treatment. (A) mRNA quantiﬁcation, normalized to
villin, of Sglt1 and Sglt2 from whole kidney section homogenates, n 10, two-tailed P values are indicated, unpaired t tests. (B and
C) Sglt1 stainings of mouse kidney sections from control and colistin-treated mice. (D to G) Sglt2 stainings. Brown areas indicate
positive staining; 20 magniﬁcation (B to E); 40 magniﬁcation of selected area within the black boxes (F and G); bars, 50 m. (H)
Na-dependent glucose uptake in BBMV isolated from control and colistin-treated mice. Values were subtracted from the respective
uptake values measured in the absence of Na and normalized to total protein content. BBMV from individual mice were assessed
separately. n 8, two-tailed P value is indicated, unpaired t test (I) Quantiﬁcation of Western blots stained for Sglt2 and pan-actin
from two independent experiments, n 10, two-tailed P value is indicated, unpaired t test. (J) Exemplary Western blot of whole
kidney membrane fractions from control (lanes 1 to 5) and colistin-treated (lanes 6 to 10) mice with stainings for Sglt2 and pan-actin,
as a loading control. L, protein ladder.
Glycosuria during Colistin-Induced Nephrotoxicity Antimicrobial Agents and Chemotherapy
December 2019 Volume 63 Issue 12 e01650-19 aac.asm.org 7
required to fully understand the reason for the lack of correlation in the increase of
these urinary biomarkers under colistin treatment. Nonetheless, glucose and Kim-1
were both detected in the urine concomitantly 24 h after treatment initiation, making
glycosuria as early of a marker as Kim-1 is considered for colistin-induced renal injury.
It has been proposed that colistin’s detergent properties may contribute to its
nephrotoxicity, which lead to increased permeability of the renal tubular epithelial cell
membrane upon protein-mediated reabsorption (endocytosis and facilitative transport)
(30, 43–47). Several studies have further suggested that colistin leads to intracellular
oxidative stress, particularly at the sites of mitochondria and the endoplasmic reticulum
(33, 47–50). Understanding whether the impaired uptake of glucose by proximal tubule
cells contributes to the onset and progression of colistin-induced kidney damage is
beyond the scope of this work. Nonetheless, it is important to point out that while
proximal tubule cells do not rely on glucose as an energy source under physiological
conditions, they shift to anaerobic glycolysis to produce the ATP required for cellular
regeneration when they experience massive mitochondrial damage (51), as has been
documented in the case of colistin-induced kidney injury (49, 52). Thus, the concomi-
tant shortage of free glucose may exacerbate the initial damage caused by colistin. It
is interesting to postulate that, particularly, the depletion of glucose, upon the accu-
mulation of colistin in the proximal tubule and induction of intracellular cell stress
through mitochondrial damage, may contribute to the high nephrotoxic potential of
this drug.
FIG 6 Sensitivity and speciﬁcity of urinary markers of colistin-induced renal injury. (A) ROC curves for urinary biomarkers Kim-1 (black),
glucose (blue), and cystatin C (green) with AUCs and P values indicated, n 13. (B) Urinary Kim-1 fold change from colistin-treated mice
plotted against urinary glucose fold change in samples collected after the last treatment. Linear regression line, Pearson’s r and P value
are indicated, n 13. (C and D) Time course of urinary glucose and Kim-1 over the course of treatment in colistin-treated mice. n 5, error
bars indicate standard deviations.
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Conclusions. The international regulatory agencies have suggested the use of an
expanded panel of biomarkers differentially expressed in various regions of the kidney
upon insult. These guidelines include CysC, Kim-1, and Ngal among others (53, 54).
Ideally, markers of kidney damage used to assess acute kidney injury should be tailored
to the medication being administered, within the knowledge available for the respec-
tive drug. Most importantly, suggestions and guidelines do not always necessarily hold
up in translation, where the accessibility of diagnostics (clinical approval, costs of
evaluation, and ease of use) of a biomarker plays a large role in facilitating its regular
use in patient care. This study conﬁrms an increase in urinary Kim-1 as a sensitive and
speciﬁc biomarker of early colistin-induced renal injury and offers glucose as an
additional urinary biomarker. Patients receiving such a last-resort therapy often suffer
from comorbidities, where the discernment of colistin-induced toxicity from general
clinical status increases the complexity of the evaluation of patient data from those
receiving colistin. Particularly, patients receiving such a treatment must be assessed
before, during, and after treatment due to the increased potential for and the acute
occurrence of kidney damage. Glycosuria is not a speciﬁc indicator of proximal tubule
damage and can also be caused by elevated serum glucose or reduced absorptive
capacity of other etiology than discussed here. Thus, some clinical conditions with an
underlying glycosuria, such as diabetes, may confound such a readout in a clinical
setting. However, we consider it probable that a reduction of Sglt2 in the proximal
tubules in diabetic patients under colistin treatment would increase underlying gly-
cosuria in a similar manner as in nondiabetic patients, albeit with higher baseline
glucose values. Further studies would be necessary to assess the general applicability
and translation of glycosuria as a biomarker of DIKI for colistin-induced nephrotoxicity
in human patient subsets, especially toward identifying quantitative cutoff values that
maximize its predictive performance. However, the readily available, clinically ap-
proved, and low cost of the diagnostic assessment of glycosuria, as well as the
sensitivity and speciﬁcity of urinary glucose as an early colistin-induced AKI marker,
certainly warrant its continued evaluation. We suggest glycosuria monitoring in a
clinical setting for patients undergoing colistin treatment as a putative option to justify
a more intense screening of the arising expanded panel of biomarkers, where diag-
nostic options may present as more costly or logistically difﬁcult. This will aid in the
identiﬁcation of patients at risk of severe and long-term renal impairment following
colistin therapy.
MATERIALS AND METHODS
Mice. Animal experiments and protocols conformed to the Guide for the Care and Use of Laboratory
Animals (U.S. National Institutes of Health) and the Swiss animal protection laws and were approved by
the Cantonal Veterinary Ofﬁce in Zurich, Switzerland (study number 186/2017). Female C57BL/6 mice
(Charles River Laboratories, Wilmington, MA) were ordered at 10 weeks of age and acclimatized for
2 weeks before beginning treatment (12 weeks old, 18 to 23 g). Mice were randomly assigned to either
colistin or PBS treatment and were housed ﬁve mice per cage in individually ventilated cages (IVCs) with
free access to food and water. Three separate experiments with a ﬁnal total of 15 mice per treatment
group were performed by two different experimenters for the data obtained in this study. Three
additional sets of kidneys from untreated mice of similar age and weight were used for brush border
membrane vesicles (BBMV) isolation for the cis-inhibition assay. A preliminary experiment was completed
with a total of 15 mice and two different colistin sulfate doses (20 mg/kg and 10 mg/kg) to determine the
dose sufﬁcient to lead to kidney injury in all treated mice, as conﬁrmed by histology.
Treatment and sample collection. Mice were treated with 20 mg/kg colistin sulfate (15,000 U/mg;
Sigma-Aldrich, St. Louis, MO) or PBS via i.p. injection for 7 consecutive days. Spontaneous urination
samples were collected during handling at various time points during treatment. Not every mouse
urinated spontaneously at every handling, leading to a sample size of 15 per treatment group for
individual time points. Mice were sacriﬁced via CO2 inhalation 24 h after the last i.p. injection/glucose
tolerance test, and serum and kidneys were harvested. Kidney tissue was either ﬁxed in 4% paraformal-
dehyde for histology, snap-frozen for protein/mRNA quantiﬁcation, and/or used directly for BBMV
isolation for transport assays.
Glucose tolerance test. Mice were starved overnight for approximately 14 h. Blood glucose was
assessed via tail tip blood sampling using a glucometer (mylife Unio; Ypsomed Distribution AG, Burgdorf,
Switzerland) before and after an i.p. injection with a 0.1-g/ml solution of D-glucose (Sigma-Aldrich, St.
Louis, MO) at a dose of 1 g/kg.
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Isolation of mouse kidney membrane fractions and immunoblot analysis. The isolation of a total
kidney membrane fraction was modiﬁed from a previously described method using one-half of a kidney
(55). After homogenization of the tissues with a Polytron in 300 mM sucrose buffer supplemented with
a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), the homogenates were centrifuged at
1,300  g in a Sorvall SS34 rotor. The supernatant was centrifuged for 1 h at 100,000  g in a Kontron
ultracentrifuge. The total kidney membrane fractions were resuspended in 300 mM sucrose with a
25-gauge needle and stored at 80°C. Protein samples (200 g) were denatured for 15 min at 65°C,
resolved on 8% (wt/vol) polyacrylamide gels, and electroblotted onto nitrocellulose membranes (GE
HealthCare, Piscataway, NJ). The membranes were blocked with 5% nonfat dry milk in PBS supplemented
with 0.1% (vol/vol) Tween 20 (PBS-T) and then incubated at 4°C overnight with a rabbit anti-Sglt2
antibody, followed by probing with a horseradish peroxidase-conjugated anti-rabbit secondary antibody.
Blots were developed with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientiﬁc,
Waltham, MA) and Fusion FX7 (Vilber Lourmat, Eberhardzell, Germany). As a loading control, the sample
blots were stripped and reprobed with anti-pan-actin (NeoMarkers, Fremont, CA).
Isolation of brush border membrane vesicles. For the cis-inhibition assay, brush border membrane
vesicles (BBMV) isolated from both kidneys of one untreated female C57BL/6 mouse were pooled. To
assess, ex vivo, the renal reabsorption of glucose after 1-week treatment with colistin, BBMV were isolated
always from the left kidney of treated mice for individual assessments. BBMV were isolated by a Mg2
precipitation method previously described (56). Excised kidneys were placed in ice-cold isolation buffer
(300 mM D-mannitol, 5 mM EGTA, 12 mM Tris-HCl, pH 7.1), homogenized with a Polytron and then mixed
with MgCl2 to a ﬁnal concentration of 12 mM. After centrifugation at 3,000  g, the supernatant was
centrifuged at 16,000  g, resuspended in vesicle buffer (300 mM D-mannitol, 20 mM HEPES, adjusted to
pH 7.4 with Tris) using a glass-Teﬂon potter, and then spun down again at 16,000  g. Finally, the BBMV
pellet was resuspended in vesicle buffer and used directly for the uptake assay and bicinchoninic acid
(BCA) assay for protein determination (Interchim, Montluçon Cedex, France).
BBMV transport assay. Uptake of glucose was measured over a 20-s interval using a rapid ﬁltration
technique as previously described (57). BBMV were preincubated at 37°C, and uptake was initiated by
injecting vesicle buffer supplemented with 100 mM NaCl and 100 M D-glucose and spiked with 5 Ci/ml
[3H]D-glucose {glucose, D-[6-3H(N)], speciﬁc activity 45.9 Ci/mmol; PerkinElmer, Switzerland}. Uptake was
measured when NaCl was replaced by an equimolar solution of KCl to determine the Na-dependent
uptake. Transport was stopped by adding 3 ml of ice-cold stop solution (300 mM D-glucose, 150 mM
NaCl, 5 mM Tris-HCl, pH 7.4) followed by ﬁltration through 0.45-m nitrocellulose acetate ﬁlter (Sartorius,
Göttingen, Germany). Afterwards, the ﬁlter was extensively washed with ice-cold stop solution and
dissolved in liquid scintillation ﬂuid (Filter Count; PerkinElmer, Switzerland) to measure radioactivity.
Uptake is expressed as picomoles of substrate per milligram of protein. For the cis-inhibition assay,
glucose uptake was assessed as described above in the presence or absence of colistin sulfate.
Histology. Five-micron kidney sections were processed for staining using microwave-based antigen
retrieval with citrate buffer (Agilent Dako, Santa Clara, CA). Primary antibodies were Kim-1 (NBP1-76701,
3809-0601A; Novus Biologicals, Centennial, CO), Ngal (ab63929; Abcam, Cambridge, UK), Sglt1 (ab14686,
GR306587-14; Abcam, Cambridge, UK), and Sglt2 (Hermann Koepsell, University of Würzburg). Horse-
radish peroxidase conjugation and detection were performed using the EnVision Dual Link System-HRP
DAB (Agilent Dako, Santa Clara, CA). Samples were immediately counterstained with Mayer’s hema-
toxylin solution (3870; Biosystems Switzerland AG, Muttenz, Switzerland). For hematoxylin and eosin Y
(HE) stainings, sections were stained with Mayer’s hematoxylin and counterstained with eosin Y solution
(Sigma-Aldrich, St. Louis, MO). Histological grading of immunostained samples on a scale of 0 (no
staining), 1 (mild), 2 (moderate), and 3 (intense) was conducted by two independent scientists in a
blinded manner, based on the intensity and area stained per sample. Severity of AKI was determined
in HE-stained samples likewise by two independent scientists on a scale of 0 to 5, with 0 being no
AKI and 5 the most severe damage, based on (i) the presence and amount of protein casts
throughout the kidney section, (ii) presence and percent area with tubular dilation throughout the
cortex, and (iii) absence and area without a visible brush border membrane in proximal tubules. The
entire kidney section was analyzed for both analyses, and a ﬁnal score was obtained by averaging
the two independently assigned values. Representative images were chosen for each ﬁgure, with a
severity grade of 0 for control images and severity grades of 3 for immunohistochemistry and 5 for
HE stainings for colistin-treated mice.
Determination of serum and urinary markers of kidney injury. Urinary glucose and serum and
urinary creatinine were measured using the colorimetric/ﬂuorometric kits ab65333 (Abcam, Cambridge,
UK) and K625 (Biovision, Milpitas, CA), respectively. Urinary cystatin C (ab201280; Abcam, Cambridge, UK),
albumin (ab108792; Abcam, Cambridge, UK), and Kim-1 (ab213477; Abcam, Cambridge, UK) were
measured by enzyme-linked immunosorbent assay (ELISA).
mRNA quantiﬁcation. Total RNA was extracted using TRIzol (Ambion by Thermo Scientiﬁc, Rockford,
IL) from one-third of the snap-frozen left kidney that was thawed on ice and minced prior to resuspen-
sion in TRIzol. Two micrograms of total RNA was reverse transcribed with random primers and Super-
script II enzyme (Invitrogen, Carlsbad, CA). Real-time PCR analysis using the generated ﬁrst-strand cDNA
was completed using the TaqMan system (Applied Biosystems, Foster City, CA). TaqMan hydrolysis
probes for Sglt1 (Mm00451203_m1), Sglt2 (Mm00453831_m1), and villin (Mm00494156_m1) were used.
Statistical analyses. All calculations and statistical analyses were performed using GraphPad Prism
version 5.
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